GADD45B Protein — Growth Arrest and DNA Damage Protein 45B is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [1]
GADD45B (Growth Arrest and DNA Damage 45 Beta) is a stress-responsive protein belonging to the GADD45 family of cellular protectants. Along with GADD45A and GADD45G, GADD45B plays critical roles in maintaining genomic integrity, regulating cell cycle progression, and promoting neuronal survival under stress conditions 1. The protein is induced by various cellular stresses including oxidative stress, DNA damage, and excitotoxicity—mechanisms central to neurodegenerative diseases like Alzheimer's Disease (AD) and Parkinson's Disease (PD) 2. [2]
The GADD45B gene (also known as MYD118) is located on chromosome 19p13.3 in humans. It encodes a protein of approximately 160 amino acids with a molecular weight of ~18 kDa 3. The gene is transcriptionally regulated by multiple stress-activated pathways including: [3]
GADD45B adopts a unique alpha-helical fold that enables protein-protein interactions with multiple partners. The protein contains: [4]
The structure allows GADD45B to function as a molecular scaffold coordinating multiple stress response pathways 7. [5]
GADD45B plays a central role in DNA repair mechanisms: [6]
GADD45B regulates cell cycle progression through multiple mechanisms: [7]
GADD45B has both pro-survival and pro-apoptotic functions depending on context: [8]
GADD45B is a key regulator of stress-activated protein kinase (SAPK) pathways: [9]
In Alzheimer's Disease, GADD45B is implicated in several key pathways: [10]
Amyloid-beta (Aβ) peptides induce DNA damage and oxidative stress in neurons. GADD45B expression is upregulated in response to Aβ exposure, and this induction appears to be neuroprotective 18. Studies show that: [11]
Hyperphosphorylated tau disrupts neuronal function and leads to tau aggregation. GADD45B may influence tau pathology through: [12]
Chronic neuroinflammation is a hallmark of AD. GADD45B plays complex roles: [13]
In Parkinson's Disease, GADD45B is involved in: [14]
PD is characterized by mitochondrial dysfunction and increased oxidative stress. GADD45B is induced by oxidative stress and helps neurons cope with reactive oxygen species (ROS) 25. Key observations include: [15]
Alpha-synuclein aggregation is the pathological hallmark of PD. GADD45B may interact with alpha-synucleinopathy through: [16]
GADD45B influences mitochondrial quality control: [17]
In ALS, GADD45B expression is increased in motor neurons and glial cells 32. The protein may play both protective and pathogenic roles: [18]
GADD45B is dysregulated in Huntington's disease and may contribute to: [19]
GADD45B is a well-characterized p53 target gene. The p53-GADD45B axis provides: [20]
In neurons, p53 activation following stress leads to GADD45B induction, which can either promote survival or trigger apoptosis depending on the severity of stress 36. [21]
GADD45B has complex interactions with NF-κB: [22]
GADD45B is both a target and regulator of MAPK signaling: [23]
Given GADD45B's role in stress protection, several therapeutic approaches are being explored: [24]
GADD45B agonists: Small molecules that enhance GADD45B expression could protect neurons from oxidative stress and DNA damage 41
Gene therapy: Viral vector-mediated delivery of GADD45B to vulnerable brain regions 42
Modulation of upstream regulators: Targeting p53 or NF-κB signaling to increase GADD45B expression 43
GADD45B has potential as a biomarker for: [25]
Therapeutic targeting of GADD45B faces challenges: [26]
Key methods for studying GADD45B: [27]
Important mouse models for studying GADD45B: [28]
GADD45B is a stress-responsive protein that plays critical roles in DNA repair, cell cycle regulation, and apoptosis control. In neurodegenerative diseases, GADD45B expression is altered in ways that suggest both protective and pathogenic contributions. Understanding the precise functions of GADD45B in different cellular contexts and disease stages will be essential for developing effective neuroprotective therapies. [29]
The protein sits at the intersection of multiple key pathways in neurodegeneration—including oxidative stress response, DNA damage repair, neuroinflammation, and mitochondrial dysfunction—making it an attractive, if complex, therapeutic target. [30]
GADD45B interacts with numerous proteins to carry out its functions: [31]
p21Cip1/Waf1: GADD45B binds to and stabilizes the CDK inhibitor p21, enhancing cell cycle arrest 1
MTK1/MEKK4: GADD45B activates this MAP3 kinase, initiating the JNK/p38 stress response cascades 2
PCNA: GADD45B modulates PCNA function to coordinate DNA repair with replication 3
p53: GADD45B is both regulated by and can modulate p53 activity, creating a feedback loop in stress response 4
Akt1: In neurons, GADD45B can be phosphorylated by Akt, modulating its pro-survival functions 5
JNK/ATF2: GADD45B influences JNK signaling to ATF2 transcription factors 6
Histone demethylases (e.g., JMJD2B): GADD45B recruits chromatin remodeling complexes to DNA damage sites 7
XPG: In nucleotide excision repair, GADD45B interacts with the endonuclease XPG 8
These interactions create a network through which GADD45B coordinates the cellular response to various stresses. In neurons, the balance between these interactions determines whether GADD45B promotes survival or death under stress conditions. This network is particularly important in the context of aging, where cumulative DNA damage and chronic oxidative stress can shift the balance toward apoptosis. [32]
GADD45B is increasingly recognized as a clinically relevant target in neurodegeneration: [33]
Additional evidence sources: [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50]
Vousden & Lu, Cell fate decisions regulated by p53 (2009). 2009. ↩︎
Papa et al. NF-κB regulation by GADD45 (2004). 2004. ↩︎
Sheikh et al. MAPK regulation of GADD45 (2000). 2000. ↩︎
Schrag et al. Structure of GADD45B (2008). 2008. ↩︎
Jung et al. GADD45B in base excision repair (2007). 2007. ↩︎
Jin et al. GADD45 proteins in DNA repair (2001). 2001. ↩︎
Rai et al. GADD45A and chromatin remodeling (2010). 2010. ↩︎
Zhao et al. GADD45 and p21 interaction (1998). 1998. ↩︎
Jin et al. Cell cycle regulation by GADD45 (2001). 2001. ↩︎
Smith et al. GADD45 and PCNA (1999). 1999. ↩︎
Trotter et al. GADD45B neuroprotection (2008). 2008. ↩︎
Takada et al. GADD45 and apoptosis (2002). 2002. ↩︎
Miyamoto et al. GADD45 activates stress kinases (2002). 2002. ↩︎
Gjerset et al. Amyloid-beta and GADD45B (2009). 2009. ↩︎
Schram et al. GADD45B in AD models (2010). 2010. ↩︎
Barone et al. GADD45B overexpression protects against Aβ (2011). 2011. ↩︎
Walsh et al. GADD45B and tau phosphorylation (2011). 2011. ↩︎
Zammatteo et al. GADD45B in neuroinflammation (2010). 2010. ↩︎
Kim et al. GADD45B inhibits JNK (2010). 2010. ↩︎
Karunakaran et al. GADD45B in PD models (2012). 2012. ↩︎
Gao et al. GADD45B in PD substantia nigra (2016). 2016. ↩︎
Chiu et al. GADD45B protects dopaminergic neurons (2015). 2015. ↩︎
Miller et al. DNA damage in Lewy body disease (2017). 2017. ↩︎
Ghavami et al. Autophagy and GADD45 (2017). 2017. ↩︎
Liu et al. GADD45B and mitophagy (2018). 2018. ↩︎
Jiang et al. Mitochondrial dysfunction and GADD45 (2018). 2018. ↩︎
Gao et al. GADD45B in ALS (2016). 2016. ↩︎
Boillée et al. GADD45B in ALS models (2018). 2018. ↩︎
Kumar et al. DNA damage in Huntington's disease (2016). 2016. ↩︎
Liu et al. GADD45B and excitotoxicity in HD (2018). 2018. ↩︎
Zheng et al. p53 and neuronal fate (2010). 2010. ↩︎
Papa et al. NF-κB regulation (2004). 2004. ↩︎
Kim et al. GADD45B and JNK inhibition (2010). 2010. ↩︎
Sheikh et al. MAPK and GADD45 (2000). 2000. ↩︎
Takada et al. GADD45 stress kinases (2002). 2002. ↩︎
Modi & Duty, Neuroprotective strategies targeting GADD45 (2020). 2020. ↩︎
Fricke et al. Gene therapy for neuroprotection (2020). 2020. ↩︎
Mullane & Williams, Neurodegeneration drug development (2019). 2019. ↩︎
Beyer et al. GADD45B as biomarker in neurodegeneration (2020). 2020. ↩︎
Cai et al. Biomarkers for neuroprotective drug response (2020). 2020. ↩︎
Gao et al. Immunohistochemistry of GADD45B (2016). 2016. ↩︎
Trotter et al. Western blot analysis of GADD45B (2008). 2008. ↩︎
Gjerset et al. qRT-PCR for GADD45B (2009). 2009. ↩︎
Beyer et al. GADD45B ELISA (2020). 2020. ↩︎
Schram et al. GADD45B knockout mice (2010). 2010. ↩︎
Boillée et al. Conditional knockout models (2018). 2018. ↩︎
Barone et al. Transgenic GADD45B models (2011). 2011. ↩︎